Investigating the platelet metabolic, AMPK-ACC signaling in Coronary Artery Disease
(2019)
Files
manuscript_these_final_kautbally_pdf_printing.pdf
Open Access - Adobe PDF
- 7.7 MB
Details
- Authors
Kautbally, Shakeel 
- Supervisors
- Abstract
- Platelets are central actors in atherosclerosis and atherothrombosis. Stimulation of the AMP-activated protein kinase (AMPK) leads to phosphorylation and inhibition of acetyl-CoA carboxylase (ACC), the first committed enzyme for the de novo fatty acids synthesis in cells, including platelets. Given the impact of atherogenic environment on platelets, we hypothesized that AMPK-ACC signaling is activated in coronary artery disease (CAD) patients. The ACCTHEROMA trial (NCT03034148) reveals platelet ACC phosphorylation (phosphoACC) as a promising marker for risk stratification in suspected CAD patients. It identifies high-risk patients and correlates with severity of coronary artery calcification. The triglycerides/high-density lipoprotein cholesterol ratio is strongly associated with increased phosphoACC, a metabolic signature of the platelet-atherogenic lipid interplay in CAD patients. Phosphorylation and inhibition of ACC impacts platelet lipid content by down-regulating triglyceride lipid species, which in turn may affect platelet functions.
- Affiliations
Citations
Kautbally, S. (2019). Investigating the platelet metabolic, AMPK-ACC signaling in Coronary Artery Disease. https://hdl.handle.net/2078.5/122816